Propofol

Evidence Level: L2

Predicted Indications: 5

Propofol

Pharmacist Assessment Report

Propofol: From General Anaesthesia and Sedation to Migraine Disorder

One-Sentence Summary

Propofol is an intravenous anaesthetic agent marketed in Canada under four active licences. The TxGNN model predicts it may be effective for migraine disorder. Currently 3 clinical trials and 20 publications support this direction, including several randomized trials in the emergency department.

Quick Overview

Item	Content
Original Indication	Not stated in the licence data compiled for this report (propofol is an intravenous anaesthetic/sedative agent)
Predicted New Indication	Migraine disorder
TxGNN Prediction Score	0.9969
Evidence Level	L2
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, propofol is a positive allosteric modulator of the GABA-A receptor. This is the basis of its sedative-hypnotic effect.

For migraine, there are two plausible links. Preclinical work shows that propofol hemisuccinate suppresses cortical spreading depression (PMID 22390898), the neural correlate of migraine aura and a possible trigger of migraine pain. Propofol may also modulate trigeminovascular nociceptive signalling.

At sub-anaesthetic doses, propofol has been used as an abortive therapy for refractory migraine in the emergency department. Its sedation and respiratory-depression risk limits use to monitored settings.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01604785	Phase 2/3	Completed	74	Low-dose propofol as abortive therapy for pediatric migraine in the emergency department. Randomization is not confirmed in the data.
NCT02485418	NA	Completed	40	Low-dose propofol infusion for pediatric migraine. Evaluates efficacy, safe dosing limits and duration of effect.
NCT02492295	NA	Terminated	12	Low-dose propofol for severe refractory migraine in the emergency department. Terminated early, so it is underpowered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29456086	2018	RCT	J Emerg Med	Prospective randomized trial of low-dose propofol for pediatric migraine in the ED.
32705801	2020	Pilot RCT	Emerg Med Australas	Procedural-sedation-dose propofol compared with standard therapy for initial migraine management in the ED.
35402989	2022	RCT	Arch Acad Emerg Med	Double-blind trial comparing propofol + granisetron with propofol + metoclopramide for acute migraine symptoms.
35573713	2022	RCT	Arch Acad Emerg Med	Sumatriptan + propofol compared with sumatriptan alone in acute migraine.
33070469	2021	RCT	Emerg Med Australas	Double-blind trial of propofol versus placebo for early resolution of acute migraine in adult ED patients.
31621134	2020	Systematic Review	Acad Emerg Med	Reviews the safety and efficacy of propofol for acute migraine in the ED. Evidence is limited.
41321235	2026	Guideline	Headache	2025 American Headache Society update on parenteral treatments for acute migraine in the ED.
24875925	2015	Systematic Review	Cephalalgia	Canadian Headache Society recommendations for migraine pain treatment in emergency settings.
27454834	2016	Review	Expert Rev Neurother	Profile of sub-anaesthetic propofol in refractory migraine.
10759925	2000	Clinical report	Headache	Early report of propofol’s effectiveness in intractable migraine in an outpatient headache centre.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02244379	PROPOFOL INJECTION	Not stated	Not stated
02018950	DIPRIVAN 1%	Not stated	Not stated
02525879	PROPOFOL INJECTION	Not stated	Not stated
02437643	PROPOFOL INJECTION	Not stated	Not stated

Safety Considerations

Disease associations from the knowledge graph (not label text): The TxGNN knowledge graph lists contraindication links with epilepsy, hypotensive disorder, respiratory failure, intracranial arteriosclerosis, inherited lipid metabolism disorder and familial hyperlipidemia.
Drug Interactions: 100 interactions were identified. Most are Moderate, and one (metronidazole) is Minor. Examples include:
- Opioids: morphine, opium.
- QT-related agents: clarithromycin, levofloxacin, ondansetron, granisetron, dolasetron, cisapride.
- Others: famotidine, loperamide, and laxatives such as bisacodyl, lactulose and magnesium citrate.
Clinical use: Sedation and respiratory depression require a monitored setting for migraine use.

Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 2/3 trial in pediatric migraine, several randomized ED trials, and a systematic review support the use of propofol in acute migraine. The evidence is limited by small sample sizes and by the need for monitored administration, so use should stay within controlled settings.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (blocking for safety screening)
Detailed mechanism of action data
Confirmation of the design (randomization) of NCT01604785 and the reason NCT02492295 was terminated
Approved indications and dosage forms for each Canadian licence
A monitoring protocol for sedation and respiratory depression, and a review of the knowledge-graph contraindications (epilepsy, hypotension, respiratory failure)

Other Predicted Indications (Brief)

Predicted Indication	Evidence Level	Decision	Note
Migraine with brainstem aura	L5	Research Question	Preclinical support only through cortical spreading depression. No aura-specific trials.
Prinzmetal angina	L5	Hold	The literature consists of case reports of coronary spasm during anaesthesia, which is a possible safety signal and not a benefit.
Nephrogenic syndrome of inappropriate antidiuresis	L5	Hold	Computational prediction only, with no supporting studies.
Tourette syndrome	L4	Hold	Evidence covers only sedation during deep brain stimulation surgery. No therapeutic effect on tics is shown.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.